On January 20, 2026, NKGen Biotech, Inc. amended a forward purchase agreement to extend its valuation date to December 31, 2026, and on January 23, 2026, it secured an additional $372,000 funding, raising its total debt to approximately $26.5 million. This filing indicates significant financial adjustments and commitments by the company.